Teladoc Health, Inc. (NYSE:TDOC) Stock Has Average Target Price of $7.54 According to Brokerages

Key Points

• Analyst sentiment is neutral: Sixteen brokerages collectively rate Teladoc Health “Hold,” with five Buys, ten Holds, and one Sell. Their average 12-month price target is $7.54.
• Recent financial performance remains weak: Teladoc reported a quarterly loss of $0.21 per share, though it beat estimates, while revenue of $606.93 million fell 4% year over year and the company maintained negative profitability metrics.
• The stock remains under pressure: TDOC opened at $6.01, below its 50-day and 200-day moving averages, while CEO Charles III sold shares to cover tax obligations; institutional investors own 76.82% of the company.

Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) has been given a consensus recommendation of "Hold" by the sixteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $7.54.

A number of research firms have recently weighed in on TDOC. Canaccord Genuity Group cut their price objective on Teladoc Health from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Thursday, July 30th. Bank of America increased their price objective on Teladoc Health from $9.00 to $10.50 and gave the company a "buy" rating in a research note on Tuesday, July 7th. Citigroup decreased their target price on Teladoc Health from $11.00 to $7.50 and set a "neutral" rating for the company in a report on Monday, August 3rd. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Teladoc Health in a research note on Wednesday, August 19th.

Teladoc Health Stock Performance

Shares of TDOC stock opened at $6.01 on Wednesday. Teladoc Health has a fifty-two week low of $4.40 and a fifty-two week high of $9.89. The company has a 50 day moving average price of $6.28 and a 200 day moving average price of $6.87. The stock has a market capitalization of $1.09 billion, a P/E ratio of -6.07 and a beta of 2.14.

Teladoc Health (NYSE:TDOC - Get Free Report) last released its earnings results on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.04. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The company had revenue of $606.93 million for the quarter, compared to analyst estimates of $615.44 million. During the same period in the prior year, the business earned ($0.19) EPS. The firm's quarterly revenue was down 4.0% on a year-over-year basis. Teladoc Health has set its Q3 2026 guidance at -0.300--0.200 EPS and its FY 2026 guidance at -1.000--0.750 EPS. On average, research analysts forecast that Teladoc Health will post -0.92 EPS for the current fiscal year.

Insider Transactions at Teladoc Health

In other news, CEO Charles III sold 17,805 shares of Teladoc Health stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $6.10, for a total value of $108,610.50. Following the completion of the transaction, the chief executive officer owned 465,535 shares in the company, valued at approximately $2,839,763.50. This trade represents a 3.68% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.70% of the stock is owned by corporate insiders.

Institutional Trading of Teladoc Health

A number of large investors have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its holdings in Teladoc Health by 1.3% during the 1st quarter. Renaissance Technologies LLC now owns 8,085,542 shares of the health services provider's stock worth $44,066,000 after buying an additional 107,400 shares during the last quarter. Pale Fire Capital SE increased its holdings in shares of Teladoc Health by 74.8% in the 1st quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider's stock valued at $18,522,000 after acquiring an additional 1,454,288 shares during the last quarter. Monaco Asset Management SAM purchased a new position in shares of Teladoc Health in the 2nd quarter valued at about $26,864,000. Quantinno Capital Management LP raised its position in shares of Teladoc Health by 128.0% during the 1st quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider's stock worth $14,287,000 after acquiring an additional 1,471,631 shares in the last quarter. Finally, Union Square Park Capital Management LLC raised its position in shares of Teladoc Health by 233.3% during the 4th quarter. Union Square Park Capital Management LLC now owns 1,000,000 shares of the health services provider's stock worth $7,000,000 after acquiring an additional 700,000 shares in the last quarter. 76.82% of the stock is currently owned by hedge funds and other institutional investors.

About Teladoc Health

Teladoc Health, Inc NYSE: TDOC provides virtual healthcare services and technology that connect patients with physicians, therapists and other healthcare professionals. Its platform supports general medical care, specialist consultations, mental health services, chronic condition management and related healthcare programs through digital and remote-care channels.

The company's offerings include Teladoc's telehealth services, BetterHelp's online counseling and therapy platform, and chronic care solutions developed through Livongo, which Teladoc acquired in 2020.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.